BBIO

MKT CAP:$14B

BridgeBio Pharma, Inc.

Market Cap

$14B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$71.25-$6.99 (-8.93%)

Apr 24, 2026

Company Details

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late...

CEO

Neil Kumar

IPO Date

Jun 27, 2019

Website

www.bridgebio.com

Key Metrics TTM

Revenue

$177M

— YoY

Net Income

-$474M

EPS (Diluted)

-$3.04

Free Cash Flow

-$220M

Revenue / Share

$0.93

Gross Margin

95.9%

Operating Margin

-304.9%

Net Margin

-267.7%

FCF Margin

-124.4%

P/S

80.4x

P/E

—

Earnings Reports

Q4 2025

May 5, 2026

PENDING

Q3 2025

Oct 29, 2025

$121MEPS -$0.96

Q2 2024

Aug 1, 2024

$2MEPS -$0.39

FY 2023

Feb 22, 2024

$9MEPS -$3.95

Q2 2021

Aug 5, 2021

$54MEPS -$0.66

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 19	$14M	$14M	-$79M
Q2 20	$0	$0	-$125M
Q2 21	$54M	$54M	-$94M
Q2 24	$2M	$2M	-$176M
Q3 25	$121M	$114M	-$145M

Valuation

Quarter	P/S	P/E
Q4 19	—	—
Q2 20	—	—
Q2 21	—	—
Q2 24	203.2x	—
Q3 25	80.4x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 19	-$76M	-$78M
Q2 20	-$88M	-$88M
Q2 21	-$92M	-$94M
Q2 24	$75M	$72M
Q3 25	-$110M	-$110M

Capital Expenditures

Quarter	CapEx
Q4 19	$2M
Q2 20	$346.0K
Q2 21	$2M
Q2 24	$2M
Q3 25	$470.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 25	+773.4%	+187.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 19	$0	0.0%
Q2 20	$0	—
Q2 21	$0	0.0%
Q2 24	$21M	989.6%
Q3 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q4 19	$57M	$35M	—
Q2 20	$87M	$38M	—
Q2 21	$102M	—	$46M
Q2 24	$115M	—	$60M
Q3 25	$113M	—	$138M

Revenue Segments

Quarter	License and Service	Product	Royalty
Q3 25	$8M	$108M	$4M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$372M	$300M	$671M
Q2 22	$470M	$246M	$716M
Q3 22	$483M	$109M	$592M
Q4 22	$377M	$95M	$472M
Q1 23	$433M	$84M	$517M
Q2 23	$302M	$81M	$384M
Q3 23	$505M	$38M	$543M
Q4 23	$376M	$59M	$435M
Q1 24	$475M	$44M	$520M
Q2 24	$547M	$40M	$587M
Q3 24	$266M	$0	$266M
Q4 24	$681M	$0	$681M
Q1 25	$541M	$0	$541M
Q2 25	$749M	$8M	$757M
Q3 25	$643M	$3M	$646M
Q4 25	$570M	$17M	$587M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 19	118M	—	—
Q2 20	117M	-0.6%	—
Q2 21	147M	+25.4%	—
Q2 24	188M	+27.8%	—
Q3 25	191M	+1.6%	+61.9%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 19	$55.7K	248
Q2 20	$0	248
Q2 21	$140.3K	385
Q2 24	$3.9K	556
Q3 25	$166.5K	725

Revenue / Employee